Work

Results from 96 Weeks Open-Label Extension of a Phase 2 Trial of Losmapimod in Subjects with FSHD: ReDUX4 (S48.008)

Year: 2023

Type: article

Source: Neurology

DOI: 10.1212/wnl.0000000000203603

Authors: Leo Wang, Jay Han, Jennifer Shoskes, John Jiang, Alrabi Tawil

Institutions: University of Washington, University of California, Irvine, Fulcrum Therapeutics (United States), University of Rochester Medicine

Language: English

Topic: Genetic Neurodegenerative Diseases

Subfield: Cellular and Molecular Neuroscience

Field: Neuroscience

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4367304269

FWCI: 0.107

Cites:

Cited by: 1

Related to: 10